Lightlake Therapeutics, Inc. has signed an agreement with a commercial contract manufacturer for the production of its naloxone-based opioid overdose reversal treatment. The manufacturer will provide the manufacturing capacity needed at cGMP production facilities to enable commercialization of the treatment on a global scale. Naloxone is an injectable drug that can reverse the overdose of prescription and illicit opioids. Lightlake has been developing an intranasal delivery system that could e...